Connect with us

Good Stocks To Buy Right Now? 3 Pharmaceutical Stocks In Focus

Check out these pharmaceutical players on the move now.
The post Good Stocks To Buy Right Now? 3 Pharmaceutical Stocks In Focus appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Published

on

3 Trending Pharmaceutical Stocks To
Watch This Week

As the global health care industry continues to deal with emerging coronavirus issues, pharmaceutical companies continue to make headlines. Accordingly, this could make pharmaceutical stocks viable plays in the stock market today. For the most part, the industry is home to companies that develop and market medications and treatments. All of which help in the diagnosis, treatment, or prevention of diseases; and also the restoring, correcting, or modifying of organic functions. Overall, the need for pharmaceuticals will, in theory, never really die down. Because of this, could pharmaceutical stocks be a staple for investors’ portfolios now?

Well, for one thing, there is no shortage of exciting news to consider in the industry now. As of earlier today, Pfizer (NYSE: PFE) is making headlines for several key factors. Firstly, it is going to acquire Arena Pharmaceuticals (NASDAQ: ARNA), a biotech firm that focuses on developing small molecule drugs. Secondly, there is also another positive update regarding its coronavirus vaccine candidate made in collaboration with BioNTech (NASDAQ: BNTX). Namely, Israeli researchers reportedly found that a three-dose course of the vaccine provides “significant protection” against the Omicron coronavirus variant. Should this be indicative of a potential growing case for booster shots, Pfizer would be in focus.

At the same time, other non-coronavirus-related pharmaceutical firms continue to press forward as well. Just last week, genome sequencing firm Pacific Biosciences (NASDAQ: PACB) announced a new collaboration with the University of California, Los Angeles (UCLA). Through this partnership, the duo are working to carry out genome sequencing for rare diseases and their causes. By and large, all this activity could reignite investor interest in pharmaceutical stocks in the stock market now. Should you be interested in the industry, here are three names to know now.

Top Pharmaceutical Stocks To Buy [Or Sell] This Week

Editas Medicine Inc.

Starting us off, we have Editas Medicine, a leading genome editing company. In essence, it focuses on translating the power and potential of the Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around the globe. It uses CRISPR technology to develop new gene-edited medicines.

On Sunday, the company reported its in vitro and in vivo preclinical data, demonstrating robust tumor reduction and clearance. The data was on the enhanced tumor-killing capacity of two modified induced pluripotent stem cell-derived natural killer (iNK) cell therapies. This was done with the company’s proprietary AsCAs12a gene editing. “In this promising research, we demonstrate the use of our proprietary engineered AsCas12a nuclease and SLEEK technology with its high efficiency, multi-transgene editing capability to enable the efficient development and evaluation of multiple iNK therapeutic approaches,” said Mark S. Shearman, Ph.D., Executive Vice President, and Chief Scientific Officer, Editas Medicine.

Last month, it also reported its third-quarter financials and provided a business update. Diving in, the company reported that it ended the quarter with $657 million in cash, cash equivalents, and marketable securities. It expects that it will be able to fund its operating expenses and capital expenditures well into 2023. It also reported that its initial clinical data for EDIT-101 for Leber Congenital Amaurosis 10, a retinal degenerative disorder demonstrated favorable safety profile and efficacy signals. Given this piece of news, is EDIT stock worth investing in right now?

pharmaceutical stocks (EDIT stock)
Source: TD Ameritrade TOS

[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know

Moderna Inc.

Moderna is a pharmaceutical company that focuses on messenger RNA (mRNA) therapeutics. Today, the company is a pharmaceutical enterprise with a diverse clinical portfolio of vaccines and therapeutics for many fields. Its progress is remarkable, with Moderna collaborating with governments around the world to allow the authorized use of one of the earliest and most effective vaccines against the pandemic.

Last Friday, the company announced positive interim Phase 1 data for its quadrivalent flu vaccine and provided an update on its program. In the study, mRNA-1010 successfully boosted titers against all four strains in older and younger adults. This includes even the lowest doses and there were no significant safety concerns observed. The company also announced that the Phase 2 study of mRNA-1010 is now fully enrolled and preparation for the Phase 3 study is underway. 

It also announced an amendment to its existing contract with Gavi, the vaccine alliance to accelerate the supply of 20 million doses to COVAX by December 31, 2021, for a total of 54 million doses made available to COVAX in 2021. These doses were included in a previously announced agreement with Gavi. They were originally scheduled for delivery in the first quarter of 2022. Given the acceleration into 2021, Moderna expects to supply up to 96.5 million doses in the first quarter of 2022 and an additional 116.5 million doses in the second quarter of 2022. Gavi retains the option to procure 233 million additional doses in 2022 under the original agreement. All things considered, is this the time to be paying attention to MRNA stock?

MRNA stock chart
Source: TD Ameritrade TOS

[Read More] Best Growth Stocks To Buy? 4 E-Commerce Stocks To Watch

Bristol-Myers Squibb Company

Another name to consider among pharmaceutical stocks today is Bristol-Myers Squibb (BMY). After all, it is among the largest pharmaceutical firms in the world today. Its portfolio focuses on a broad range of disease areas, including oncology, cardiovascular, immunoscience, fibrosis and others. Given BMY’s presence in the pharmaceuticals industry, BMY stock could be worth keeping an eye on.

For one thing, the company continues to reward its investors. Evidently, BMY raised its quarterly dividend earlier today. To elaborate, BMY stock now comes with a quarterly dividend payout of $0.54 per share. This is a solid 10.2% year-over-year rise from the same quarter last year. Moreover, the increase also marks BMY’s 13th consecutive fiscal year increasing its dividend payouts.

Not to mention, the company is also authorizing an additional $15 billion in its multi-year share repurchase program. All in all, CEO Giovanni Caforio had this to say, “The company’s financial position is strong, and we remain committed to a consistent, balanced capital allocation strategy.” Furthermore, Caforio also adds that BMY is currently looking at a free cash flow of about $45 billion to $50 billion between 2021 and 2023. With the company’s strong balance sheet in mind, would you consider BMY stock a top buy?

BMY stock
Source: TD Ameritrade TOS

The post Good Stocks To Buy Right Now? 3 Pharmaceutical Stocks In Focus appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Uncategorized

Homes listed for sale in early June sell for $7,700 more

New Zillow research suggests the spring home shopping season may see a second wave this summer if mortgage rates fall
The post Homes listed for sale in…

Published

on

  • A Zillow analysis of 2023 home sales finds homes listed in the first two weeks of June sold for 2.3% more. 
  • The best time to list a home for sale is a month later than it was in 2019, likely driven by mortgage rates.
  • The best time to list can be as early as the second half of February in San Francisco, and as late as the first half of July in New York and Philadelphia. 

Spring home sellers looking to maximize their sale price may want to wait it out and list their home for sale in the first half of June. A new Zillow® analysis of 2023 sales found that homes listed in the first two weeks of June sold for 2.3% more, a $7,700 boost on a typical U.S. home.  

The best time to list consistently had been early May in the years leading up to the pandemic. The shift to June suggests mortgage rates are strongly influencing demand on top of the usual seasonality that brings buyers to the market in the spring. This home-shopping season is poised to follow a similar pattern as that in 2023, with the potential for a second wave if the Federal Reserve lowers interest rates midyear or later. 

The 2.3% sale price premium registered last June followed the first spring in more than 15 years with mortgage rates over 6% on a 30-year fixed-rate loan. The high rates put home buyers on the back foot, and as rates continued upward through May, they were still reassessing and less likely to bid boldly. In June, however, rates pulled back a little from 6.79% to 6.67%, which likely presented an opportunity for determined buyers heading into summer. More buyers understood their market position and could afford to transact, boosting competition and sale prices.

The old logic was that sellers could earn a premium by listing in late spring, when search activity hit its peak. Now, with persistently low inventory, mortgage rate fluctuations make their own seasonality. First-time home buyers who are on the edge of qualifying for a home loan may dip in and out of the market, depending on what’s happening with rates. It is almost certain the Federal Reserve will push back any interest-rate cuts to mid-2024 at the earliest. If mortgage rates follow, that could bring another surge of buyers later this year.

Mortgage rates have been impacting affordability and sale prices since they began rising rapidly two years ago. In 2022, sellers nationwide saw the highest sale premium when they listed their home in late March, right before rates barreled past 5% and continued climbing. 

Zillow’s research finds the best time to list can vary widely by metropolitan area. In 2023, it was as early as the second half of February in San Francisco, and as late as the first half of July in New York. Thirty of the top 35 largest metro areas saw for-sale listings command the highest sale prices between May and early July last year. 

Zillow also found a wide range in the sale price premiums associated with homes listed during those peak periods. At the hottest time of the year in San Jose, homes sold for 5.5% more, a $88,000 boost on a typical home. Meanwhile, homes in San Antonio sold for 1.9% more during that same time period.  

 

Metropolitan Area Best Time to List Price Premium Dollar Boost
United States First half of June 2.3% $7,700
New York, NY First half of July 2.4% $15,500
Los Angeles, CA First half of May 4.1% $39,300
Chicago, IL First half of June 2.8% $8,800
Dallas, TX First half of June 2.5% $9,200
Houston, TX Second half of April 2.0% $6,200
Washington, DC Second half of June 2.2% $12,700
Philadelphia, PA First half of July 2.4% $8,200
Miami, FL First half of June 2.3% $12,900
Atlanta, GA Second half of June 2.3% $8,700
Boston, MA Second half of May 3.5% $23,600
Phoenix, AZ First half of June 3.2% $14,700
San Francisco, CA Second half of February 4.2% $50,300
Riverside, CA First half of May 2.7% $15,600
Detroit, MI First half of July 3.3% $7,900
Seattle, WA First half of June 4.3% $31,500
Minneapolis, MN Second half of May 3.7% $13,400
San Diego, CA Second half of April 3.1% $29,600
Tampa, FL Second half of June 2.1% $8,000
Denver, CO Second half of May 2.9% $16,900
Baltimore, MD First half of July 2.2% $8,200
St. Louis, MO First half of June 2.9% $7,000
Orlando, FL First half of June 2.2% $8,700
Charlotte, NC Second half of May 3.0% $11,000
San Antonio, TX First half of June 1.9% $5,400
Portland, OR Second half of April 2.6% $14,300
Sacramento, CA First half of June 3.2% $17,900
Pittsburgh, PA Second half of June 2.3% $4,700
Cincinnati, OH Second half of April 2.7% $7,500
Austin, TX Second half of May 2.8% $12,600
Las Vegas, NV First half of June 3.4% $14,600
Kansas City, MO Second half of May 2.5% $7,300
Columbus, OH Second half of June 3.3% $10,400
Indianapolis, IN First half of July 3.0% $8,100
Cleveland, OH First half of July  3.4% $7,400
San Jose, CA First half of June 5.5% $88,400

 

The post Homes listed for sale in early June sell for $7,700 more appeared first on Zillow Research.

Read More

Continue Reading

Government

Survey Shows Declining Concerns Among Americans About COVID-19

Survey Shows Declining Concerns Among Americans About COVID-19

A new survey reveals that only 20% of Americans view covid-19 as "a major threat"…

Published

on

Survey Shows Declining Concerns Among Americans About COVID-19

A new survey reveals that only 20% of Americans view covid-19 as "a major threat" to the health of the US population - a sharp decline from a high of 67% in July 2020.

(SARMDY/Shutterstock)

What's more, the Pew Research Center survey conducted from Feb. 7 to Feb. 11 showed that just 10% of Americans are concerned that they will  catch the disease and require hospitalization.

"This data represents a low ebb of public concern about the virus that reached its height in the summer and fall of 2020, when as many as two-thirds of Americans viewed COVID-19 as a major threat to public health," reads the report, which was published March 7.

According to the survey, half of the participants understand the significance of researchers and healthcare providers in understanding and treating long COVID - however 27% of participants consider this issue less important, while 22% of Americans are unaware of long COVID.

What's more, while Democrats were far more worried than Republicans in the past, that gap has narrowed significantly.

"In the pandemic’s first year, Democrats were routinely about 40 points more likely than Republicans to view the coronavirus as a major threat to the health of the U.S. population. This gap has waned as overall levels of concern have fallen," reads the report.

More via the Epoch Times;

The survey found that three in ten Democrats under 50 have received an updated COVID-19 vaccine, compared with 66 percent of Democrats ages 65 and older.

Moreover, 66 percent of Democrats ages 65 and older have received the updated COVID-19 vaccine, while only 24 percent of Republicans ages 65 and older have done so.

“This 42-point partisan gap is much wider now than at other points since the start of the outbreak. For instance, in August 2021, 93 percent of older Democrats and 78 percent of older Republicans said they had received all the shots needed to be fully vaccinated (a 15-point gap),” it noted.

COVID-19 No Longer an Emergency

The U.S. Centers for Disease Control and Prevention (CDC) recently issued its updated recommendations for the virus, which no longer require people to stay home for five days after testing positive for COVID-19.

The updated guidance recommends that people who contracted a respiratory virus stay home, and they can resume normal activities when their symptoms improve overall and their fever subsides for 24 hours without medication.

“We still must use the commonsense solutions we know work to protect ourselves and others from serious illness from respiratory viruses, this includes vaccination, treatment, and staying home when we get sick,” CDC director Dr. Mandy Cohen said in a statement.

The CDC said that while the virus remains a threat, it is now less likely to cause severe illness because of widespread immunity and improved tools to prevent and treat the disease.

Importantly, states and countries that have already adjusted recommended isolation times have not seen increased hospitalizations or deaths related to COVID-19,” it stated.

The federal government suspended its free at-home COVID-19 test program on March 8, according to a website set up by the government, following a decrease in COVID-19-related hospitalizations.

According to the CDC, hospitalization rates for COVID-19 and influenza diseases remain “elevated” but are decreasing in some parts of the United States.

Tyler Durden Sun, 03/10/2024 - 22:45

Read More

Continue Reading

Government

Rand Paul Teases Senate GOP Leader Run – Musk Says “I Would Support”

Rand Paul Teases Senate GOP Leader Run – Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump…

Published

on

Rand Paul Teases Senate GOP Leader Run - Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump into the race to become the next Senate GOP leader, and Elon Musk was quick to support the idea. Republicans must find a successor for periodically malfunctioning Mitch McConnell, who recently announced he'll step down in November, though intending to keep his Senate seat until his term ends in January 2027, when he'd be within weeks of turning 86. 

So far, the announced field consists of two quintessential establishment types: John Cornyn of Texas and John Thune of South Dakota. While John Barrasso's name had been thrown around as one of "The Three Johns" considered top contenders, the Wyoming senator on Tuesday said he'll instead seek the number two slot as party whip. 

Paul used X to tease his potential bid for the position which -- if the GOP takes back the upper chamber in November -- could graduate from Minority Leader to Majority Leader. He started by telling his 5.1 million followers he'd had lots of people asking him about his interest in running...

...then followed up with a poll in which he predictably annihilated Cornyn and Thune, taking a 96% share as of Friday night, with the other two below 2% each. 

Elon Musk was quick to back the idea of Paul as GOP leader, while daring Cornyn and Thune to follow Paul's lead by throwing their names out for consideration by the Twitter-verse X-verse. 

Paul has been a stalwart opponent of security-state mass surveillance, foreign interventionism -- to include shoveling billions of dollars into the proxy war in Ukraine -- and out-of-control spending in general. He demonstrated the latter passion on the Senate floor this week as he ridiculed the latest kick-the-can spending package:   

In February, Paul used Senate rules to force his colleagues into a grueling Super Bowl weekend of votes, as he worked to derail a $95 billion foreign aid bill. "I think we should stay here as long as it takes,” said Paul. “If it takes a week or a month, I’ll force them to stay here to discuss why they think the border of Ukraine is more important than the US border.”

Don't expect a Majority Leader Paul to ditch the filibuster -- he's been a hardy user of the legislative delay tactic. In 2013, he spoke for 13 hours to fight the nomination of John Brennan as CIA director. In 2015, he orated for 10-and-a-half-hours to oppose extension of the Patriot Act

Rand Paul amid his 10 1/2 hour filibuster in 2015

Among the general public, Paul is probably best known as Capitol Hill's chief tormentor of Dr. Anthony Fauci, who was director of the National Institute of Allergy and Infectious Disease during the Covid-19 pandemic. Paul says the evidence indicates the virus emerged from China's Wuhan Institute of Virology. He's accused Fauci and other members of the US government public health apparatus of evading questions about their funding of the Chinese lab's "gain of function" research, which takes natural viruses and morphs them into something more dangerous. Paul has pointedly said that Fauci committed perjury in congressional hearings and that he belongs in jail "without question."   

Musk is neither the only nor the first noteworthy figure to back Paul for party leader. Just hours after McConnell announced his upcoming step-down from leadership, independent 2024 presidential candidate Robert F. Kennedy, Jr voiced his support: 

In a testament to the extent to which the establishment recoils at the libertarian-minded Paul, mainstream media outlets -- which have been quick to report on other developments in the majority leader race -- pretended not to notice that Paul had signaled his interest in the job. More than 24 hours after Paul's test-the-waters tweet-fest began, not a single major outlet had brought it to the attention of their audience. 

That may be his strongest endorsement yet. 

Tyler Durden Sun, 03/10/2024 - 20:25

Read More

Continue Reading

Trending